Loading
A phase 2 trial of Relmacabtagene autoleucel in hodgkin lymphoma and non-hodgkin lymphoma, run by Shanghai Ming Ju Biotechnology Co., Ltd., now recruiting.
CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma is a phase 2 interventional study registered as NCT06479356 by Shanghai Ming Ju Biotechnology Co., Ltd., with 12 participants planned, started 2024-08-15 and due to reach its primary completion in 2025-04-30. Interventions recorded: Relma-cel. Conditions listed: Non-Hodgkin Lymphoma, Large B-cell Lymphoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Relmacabtagene autoleucel, JW Therapeutics, CAR-T cell therapy.
Shares Relmacabtagene autoleucel, JW Therapeutics, CAR-T cell therapy.
Shares Relmacabtagene autoleucel, JW Therapeutics.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/